查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1593741

胃肠道药物市场评估：按药物类型、药物类别、给药途径、应用、分销管道和地区划分的机会和预测（2017-2031）

Gastrointestinal Drugs Market Assessment, By Drug Type, By Drug Class, By Route of Administration, By Application, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 240 Pages | 商品交期: 3-5个工作天内

价格

全球胃肠道药物市场规模预计将从 2023 年的 452 亿美元增长到 2031 年的 629.6 亿美元，预测期内复合年增长率为 4.23%。

推动市场成长的因素包括胃肠道疾病患者数量的增加、市场进入者推出新产品以及确保胃肠道药物在全球不同地区的可用性，例如对胃肠道疾病的关注。

药物传递机制和配方的技术进步正在提高胃肠道药物的有效性。这项进步包括开发延长和延迟释放製剂，以提高药物的生物利用度和吸收并改善患者的治疗效果。这些进展正在彻底改变溃疡性结肠炎和克隆氏症等疾病的治疗方法，为市场创造利润丰厚的成长机会。

乳糜泻等各种胃肠道疾病盛行率的上升也推动了全球胃肠道药物市场的成长。根据 StatPearls Publishing LLC 于 2023 年 8 月在 StatPearls 杂誌上发表的一篇文章，乳糜泻的盛行率约为总人口的 0.5% 至 1%。此外，克罗恩病患者的数量正在迅速增加。美国国家糖尿病、消化和肾臟疾病研究所估计，美国有超过 50 万人患有克隆氏症。因此，各製药公司正在投资研究工作，以加强新疗法的开发，以对抗克罗恩病日益严重的威胁。

本报告调查了全球胃肠道药物市场，提供了市场定义和概述、市场规模趋势和预测、各个细分市场/地区/主要国家的详细分析、行业结构以及影响因素的市场成长分析、案例研究、竞争格局和主要公司概况。

目录

第一章专案范围与定义

第二章研究方法

第 3 章执行摘要

第四章全球胃肠道药物市场展望

  • 市场规模分析与预测
  • 市占率分析/预测
    • 依药物类型
    • 依药物类别
    • 依给药途径
    • 依用途
    • 按分销管道
    • 按地区
    • 按公司划分的市占率分析
  • 市场地图分析

第五章北美胃肠道药物市场展望

  • 市场规模分析与预测
  • 市占率分析/预测
  • 国家市场评估
    • 美国
    • 加拿大
    • 墨西哥

第六章欧洲胃肠道药物市场展望

  • 德国
  • 法国
  • 义大利
  • 英国
  • 俄罗斯
  • 荷兰
  • 西班牙
  • 土耳其
  • 波兰

第七章亚太胃肠道药物市场展望

  • 印度
  • 中国
  • 日本
  • 澳大利亚
  • 越南
  • 韩国
  • 印尼
  • 菲律宾

第八章南美洲胃肠道药物市场展望

  • 巴西
  • 阿根廷

第九章中东和非洲胃肠道药物市场展望

  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第10章供需分析

第 11 章汇入/汇出分析

第十二章价值链分析

第 13 章波特五力分析

第14章PESTLE分析

第十五章价格分析

第 16 章市场动态

  • 市场驱动因素
  • 市场课题

第十七章市场趋势与发展

第 18 章法律与监管架构/创新

第十九章专利状况

第 20 章个案研究

第21章竞争态势

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 名的公司的 SWOT 分析
  • 前10名企业状况
    • AstraZeneca PLC
    • Boehringer Ingelheim International GmbH
    • Pfizer Inc.
    • Takeda Pharmaceutical Company Limited
    • AbbVie Inc.
    • Bristol-Myers Squibb Company
    • Bayer AG
    • Abbott Laboratories
    • Johnson & Johnson Services, Inc. (Janssen Global Services, LLC)
    • GlaxoSmithKline plc

第 22 章策略建议

第23章关于我们公司/免责声明

Product Code: MX12253

Global gastrointestinal drugs market is projected to witness a CAGR of 4.23% during the forecast period 2024-2031, growing from USD 45.20 billion in 2023 to USD 62.96 billion in 2031. The market's growth is boosted by the rising cases of gastrointestinal diseases, novel product launches by the market players, and increasing emphasis on ensuring the availability of gastrointestinal drugs in different regions across the globe.

Technological advancements in drug delivery mechanisms and formulations are enhancing the efficacy of gastrointestinal drugs. The advancements include the development of extended-release and delayed-release formulations that aid in improving the bioavailability and absorption of the drugs, resulting in improved patient outcomes. Such developments are revolutionizing the treatment of ulcerative colitis and Crohn's disease, among others, providing lucrative growth opportunities for the market.

The rising prevalence of various gastrointestinal disorders, such as celiac disease, is also propelling the growth of the global gastrointestinal drugs market. According to an article published in the StatPearls journal of StatPearls Publishing LLC in August 2023, the prevalence of celiac disease is approximately 0.5% to 1% among the general population. Additionally, the number of cases of Crohn's disease is also increasing at a rapid rate. According to the estimates of the National Institute of Diabetes and Digestive and Kidney Diseases, more than half a million people are suffering from Crohn's disease in the United States. Thus, various pharmaceutical companies are investing in research activities to augment the development of novel therapies to combat the growing threat of Crohn's disease. In October 2023, Eli Lilly and Company announced that the investigational interleukin-23p19 antagonist, mirikizumab met all major secondary and co-primary endpoints in a phase 3 study, evaluating its efficacy and safety for treating adults with severely to moderately active Crohn's disease.

Increasing Cases of Gastrointestinal Diseases Boost Market Demand

The rising cases of gastrointestinal distress in various regions across the globe due to changes in lifestyle and eating habits of the population is one of the major factors bolstering the global gastrointestinal drugs market demand. Factors such as increased stress and the rising prevalence of obesity are also propelling the incidences of gastrointestinal diseases. According to the estimates of the World Health Organization (WHO), 1 in 8 people around the world were living with obesity in 2022. This increase is augmenting the incidences of diseases such as peptic ulcers, irritable bowel syndrome, and gastroesophageal reflux disease. Furthermore, the rapid expansion of the aging population is also boosting the demand for gastrointestinal drugs as the older population is more susceptible to gastrointestinal issues. The WHO estimates that approximately 1 in 6 people across the globe will be 60 or older by 2030. Due to the rising occurrences of such issues, pharmaceutical companies are also increasingly focusing on developing innovative therapies that address the underlying cause of the disease rather than alleviating symptoms.

Rising Efforts of Pharma Companies Supports Market Expansion

The rising efforts of the key players in the market to ensure the availability of novel gastrointestinal drugs through investments and partnerships is boosting the global gastrointestinal drugs market size. In June 2024, AbbVie Inc. secured its position in the gastrointestinal drugs market by paying USD 150 million to China-based FutureGen Biopharmaceutical (Beijing) Co., Ltd. in near-term fees for rights to antibody drug targeting TL1A molecule that has been linked with a heightened immune response in cases of inflammatory bowel disease.

Similarly, in June 2024, Akum Drugs and Pharmaceuticals Ltd. unveiled new formulations for gastrointestinal diseases for patients in India. The company's Rabeprazole + Levosulpiride SR Capsules received approval from the Drug Controller General of India (DCGI). The drugs aim to provide relief to patients suffering from gastrointestinal tract disorders. Rabeprazole sodium, a potent antisecretory compound, has demonstrated efficacy in treating duodenal and gastric ulcers along with gastroesophageal reflux disease by selectively inhibiting the secretion of gastric acid. Such efforts are expected to aid patients suffering from gastrointestinal issues in effectively managing their conditions and provide lucrative growth opportunities to the gastrointestinal drug market.

Retail Pharmacies Hold Significant Market Share

The segment's expansion can be attributed to the rising requirement for over-the-counter (OTC) gastrointestinal drugs over the past few years due to the rising cases of gastrointestinal distress and consumer preference for immediate relief from common digestive issues, including constipation, acid reflux, diarrhea, and heartburn. As per the American College of Gastroenterology (ACG) estimates, approximately 20% of the population of the United States suffers from gastroesophageal reflux disease. Due to the widespread presence of retail pharmacies and their convenient nature, patients suffering from gastrointestinal issues prefer them for purchasing medication, especially in semi-urban and urban locations.

Meanwhile, online pharmacies are expected to grow rapidly over the next few years due to the growing preference for online shopping, fast delivery, shipping, and the availability of lucrative discounts. Other advantages online pharmacies offer include increased consumer accessibility to a broad range of products. Additionally, the growing popularity of digital consultation and the rising availability of e-prescriptions have also made it easier for patients to avail themselves of the required medications through online pharmacies, bolstering the segment's growth.

North America Holds Major Market Share

The growth of the North American gastrointestinal drugs market can be attributed to the increasing efforts of the leading market players based in the region to ensure novel product launches, rising cases of gastrointestinal diseases, and the presence of well-established healthcare and pharmaceutical sectors. Various gastrointestinal diseases, including ulcerative colitis, Crohn's disease, and inflammatory bowel disease, are becoming increasingly prevalent in the United States, bolstering the market's demand. As per the estimates of the US Centers for Disease Control and Prevention, the prevalence of inflammatory bowel disease is between 2.4 and 3.1 million in the United States, with differing burdens across groups. Additionally, the prominent presence of various research organizations that are increasingly focusing on investigating different gastrointestinal diseases is also expected to influence the market's expansion positively. Moreover, the increasing availability of novel drugs due to the increasing provision of approvals by the regulatory bodies in the region is also supporting the market's growth is the region. In 2023, the US Food and Drug Administration (FDA) provided approval to five new gastrointestinal targeted drugs, including colonoscopy prep, inflammatory bowel disease, and gastroesophageal reflux disease. Such approvals are expected to increase the influx of various gastrointestinal drugs in North America.

Future Market Scenario (2024-2031F)

As per the global gastrointestinal drugs market analysis, the market is expected to witness significant growth in the coming years due to the growing burden of different gastrointestinal diseases and the increasing efforts of the market players towards novel product launches. According to an article published in January 2024 in the Dovepress of the Dove Medical Press Ltd, the prevalence of Crohn's disease is expected to increase to 1% in 2030 in Western European countries and the United States. This increase will bolster the market's demand to meet the growing drug requirement for effective management and treatment of the condition. The cases of gastrointestinal distress are also expected to increase in the coming years due to the increasing preference for fast foods and dining out as a fast food-filled diet lacks essential fiber intake, resulting in decreased adoption of water.

Additionally, the market is also expected to witness significant growth over the forecast period due to the rising investments by the leading pharmaceutical companies towards research and development activities and the emphasis on creating targeted therapies that provide minimal side effects along with long-term relief. Furthermore, the growing efforts of various countries to enhance their healthcare sectors and ensure the availability of necessary therapies and treatment solutions are further expected to propel the global gastrointestinal drugs market growth.

Key Players Landscape and Outlook

The market's growth is bolstered by the rising collaborations by the key players of the market with leading pharma companies across the globe to introduce their products to different countries. In June 2024, Sun Pharmaceutical Industries, Inc. inked a licensing agreement with Takeda Pharmaceutical Company Limited to commercialize their new gastrointestinal drug in India. The former entered into a non-exclusive patent licensing agreement for commercializing Takeda's Vonoprazan tablets, which are 20 and 10 mg in strength and are used for treating reflux esophagitis, among other acid peptic disorders. Such partnerships are expected to aid the market players in expanding their global footprint and demonstrate their commitment to ensuring that healthcare professionals and patients are provided with novel treatment options to manage gastrointestinal diseases and disorders effectively.

Additionally, the key players in the market are also working on introducing novel drugs for managing various gastrointestinal diseases. In June 2024, Johnson & Johnson Services, Inc. submitted a supplemental Biologics License Application (sBLA) to the US FDA to seek approval for TREMFYA, used for treating adults with moderate to severe active Crohn's disease. Such efforts are expected to aid the company in expanding its product portfolio and increasing its market share.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Gastrointestinal Drugs Market Outlook, 2017-2031F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Drug Type
      • 4.2.1.1. Branded
      • 4.2.1.2. Generic
    • 4.2.2. By Drug Class
      • 4.2.2.1. Biologics
      • 4.2.2.2. Proton Pump Inhibitors
      • 4.2.2.3. Aminosalicylates
      • 4.2.2.4. Antacids
      • 4.2.2.5. Laxatives
      • 4.2.2.6. H2 Antagonists
      • 4.2.2.7. Others
    • 4.2.3. By Route of Administration
      • 4.2.3.1. Oral
      • 4.2.3.2. Parenteral
      • 4.2.3.3. Rectal
    • 4.2.4. By Application
      • 4.2.4.1. Ulcerative Colitis
      • 4.2.4.2. Irritable Bowel Syndrome
      • 4.2.4.3. Crohn's Disease
      • 4.2.4.4. Celiac Disease
      • 4.2.4.5. Gastroenteritis
      • 4.2.4.6. Others
    • 4.2.5. By Distribution Channel
      • 4.2.5.1. Hospital Pharmacies
      • 4.2.5.2. Retail Pharmacies
      • 4.2.5.3. Online Pharmacies
    • 4.2.6. By Region
      • 4.2.6.1. North America
      • 4.2.6.2. Europe
      • 4.2.6.3. Asia-Pacific
      • 4.2.6.4. South America
      • 4.2.6.5. Middle East and Africa
    • 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 4.3. Market Map Analysis, 2023
    • 4.3.1. By Drug Type
    • 4.3.2. By Drug Class
    • 4.3.3. By Route of Administration
    • 4.3.4. By Application
    • 4.3.5. By Distribution Channel
    • 4.3.6. By Region

5. North America Gastrointestinal Drugs Market Outlook, 2017-2031F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Drug Type
      • 5.2.1.1. Branded
      • 5.2.1.2. Generic
    • 5.2.2. By Drug Class
      • 5.2.2.1. Biologics
      • 5.2.2.2. Proton Pump Inhibitors
      • 5.2.2.3. Aminosalicylates
      • 5.2.2.4. Antacids
      • 5.2.2.5. Laxatives
      • 5.2.2.6. H2 Antagonists
      • 5.2.2.7. Others
    • 5.2.3. By Route of Administration
      • 5.2.3.1. Oral
      • 5.2.3.2. Parenteral
      • 5.2.3.3. Rectal
    • 5.2.4. By Application
      • 5.2.4.1. Ulcerative Colitis
      • 5.2.4.2. Irritable Bowel Syndrome
      • 5.2.4.3. Crohn's Disease
      • 5.2.4.4. Celiac Disease
      • 5.2.4.5. Gastroenteritis
      • 5.2.4.6. Others
    • 5.2.5. By Distribution Channel
      • 5.2.5.1. Hospital Pharmacies
      • 5.2.5.2. Retail Pharmacies
      • 5.2.5.3. Online Pharmacies
    • 5.2.6. By Country Share
      • 5.2.6.1. United States
      • 5.2.6.2. Canada
      • 5.2.6.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Gastrointestinal Drugs Market Outlook, 2017-2031F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Drug Type
          • 5.3.1.2.1.1. Branded
          • 5.3.1.2.1.2. Generic
        • 5.3.1.2.2. By Drug Class
          • 5.3.1.2.2.1. Biologics
          • 5.3.1.2.2.2. Proton Pump Inhibitors
          • 5.3.1.2.2.3. Aminosalicylates
          • 5.3.1.2.2.4. Antacids
          • 5.3.1.2.2.5. Laxatives
          • 5.3.1.2.2.6. H2 Antagonists
          • 5.3.1.2.2.7. Others
        • 5.3.1.2.3. By Route of Administration
          • 5.3.1.2.3.1. Oral
          • 5.3.1.2.3.2. Parenteral
          • 5.3.1.2.3.3. Rectal
        • 5.3.1.2.4. By Application
          • 5.3.1.2.4.1. Ulcerative Colitis
          • 5.3.1.2.4.2. Irritable Bowel Syndrome
          • 5.3.1.2.4.3. Crohn's Disease
          • 5.3.1.2.4.4. Celiac Disease
          • 5.3.1.2.4.5. Gastroenteritis
          • 5.3.1.2.4.6. Others
        • 5.3.1.2.5. By Distribution Channel
          • 5.3.1.2.5.1. Hospital Pharmacies
          • 5.3.1.2.5.2. Retail Pharmacies
          • 5.3.1.2.5.3. Online Pharmacies
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Gastrointestinal Drugs Market Outlook, 2017-2031F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Gastrointestinal Drugs Market Outlook, 2017-2031F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Gastrointestinal Drugs Market Outlook, 2017-2031F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Gastrointestinal Drugs Market Outlook, 2017-2031F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Import and Export Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

  • 18.1. Clinical Trials
  • 18.2. Regulatory Approvals

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

  • 21.1. Competition Matrix of Top 5 Market Leaders
  • 21.2. SWOT Analysis for Top 5 Players
  • 21.3. Key Players Landscape for Top 10 Market Players
    • 21.3.1. AstraZeneca PLC
      • 21.3.1.1. Company Details
      • 21.3.1.2. Key Management Personnel
      • 21.3.1.3. Products and Services
      • 21.3.1.4. Financials (As Reported)
      • 21.3.1.5. Key Market Focus and Geographical Presence
      • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
    • 21.3.2. Boehringer Ingelheim International GmbH
    • 21.3.3. Pfizer Inc.
    • 21.3.4. Takeda Pharmaceutical Company Limited
    • 21.3.5. AbbVie Inc.
    • 21.3.6. Bristol-Myers Squibb Company
    • 21.3.7. Bayer AG
    • 21.3.8. Abbott Laboratories
    • 21.3.9. Johnson & Johnson Services, Inc. (Janssen Global Services, LLC)
    • 21.3.10. GlaxoSmithKline plc

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 3. Global Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 4. Global Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 5. Global Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 6. Global Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 7. Global Gastrointestinal Drugs Market Share (%), By Region, 2017-2031F
  • Figure 8. North America Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 9. North America Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 10. North America Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 11. North America Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 12. North America Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 13. North America Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 14. North America Gastrointestinal Drugs Market Share (%), By Country, 2017-2031F
  • Figure 15. United States Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. United States Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 17. United States Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 18. United States Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 19. United States Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 20. United States Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 21. Canada Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. Canada Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 23. Canada Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 24. Canada Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 25. Canada Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 26. Canada Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 27. Mexico Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Mexico Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 29. Mexico Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 30. Mexico Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 31. Mexico Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 32. Mexico Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 33. Europe Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 34. Europe Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 35. Europe Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 36. Europe Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 37. Europe Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 38. Europe Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 39. Europe Gastrointestinal Drugs Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Germany Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 42. Germany Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 43. Germany Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 44. Germany Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 45. Germany Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 46. France Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. France Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 48. France Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 49. France Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 50. France Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 51. France Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 52. Italy Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Italy Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 54. Italy Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 55. Italy Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 56. Italy Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 57. Italy Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 58. United Kingdom Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. United Kingdom Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 60. United Kingdom Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 61. United Kingdom Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 62. United Kingdom Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 63. United Kingdom Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 64. Russia Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Russia Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 66. Russia Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 67. Russia Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 68. Russia Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 69. Russia Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 70. Netherlands Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 71. Netherlands Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 72. Netherlands Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 73. Netherlands Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 74. Netherlands Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 75. Netherlands Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 76. Spain Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Spain Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 78. Spain Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 79. Spain Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 80. Spain Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 81. Spain Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 82. Turkey Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. Turkey Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 84. Turkey Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 85. Turkey Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 86. Turkey Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 87. Turkey Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 88. Poland Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Poland Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 90. Poland Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 91. Poland Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 92. Poland Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 93. Poland Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 94. South America Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. South America Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 96. South America Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 97. South America Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 98. South America Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 99. South America Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 100. South America Gastrointestinal Drugs Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Brazil Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 103. Brazil Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 104. Brazil Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 105. Brazil Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 106. Brazil Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 107. Argentina Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 108. Argentina Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 109. Argentina Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 110. Argentina Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 111. Argentina Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 112. Argentina Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 113. Asia-Pacific Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 114. Asia-Pacific Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 115. Asia-Pacific Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 116. Asia-Pacific Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 117. Asia-Pacific Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 118. Asia-Pacific Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 119. Asia-Pacific Gastrointestinal Drugs Market Share (%), By Country, 2017-2031F
  • Figure 120. India Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 121. India Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 122. India Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 123. India Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 124. India Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 125. India Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 126. China Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. China Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 128. China Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 129. China Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 130. China Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 131. China Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 132. Japan Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 133. Japan Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 134. Japan Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 135. Japan Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 136. Japan Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 137. Japan Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 138. Australia Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 139. Australia Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 140. Australia Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 141. Australia Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 142. Australia Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 143. Australia Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 144. Vietnam Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 145. Vietnam Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 146. Vietnam Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 147. Vietnam Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 148. Vietnam Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 149. Vietnam Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 150. South Korea Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. South Korea Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 152. South Korea Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 153. South Korea Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 154. South Korea Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 155. South Korea Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 156. Indonesia Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 157. Indonesia Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 158. Indonesia Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 159. Indonesia Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 160. Indonesia Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 161. Indonesia Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 162. Philippines Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 163. Philippines Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 164. Philippines Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 165. Philippines Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 166. Philippines Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 167. Philippines Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 168. Middle East & Africa Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 169. Middle East & Africa Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 170. Middle East & Africa Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 171. Middle East & Africa Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 172. Middle East & Africa Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 173. Middle East & Africa Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 174. Middle East & Africa Gastrointestinal Drugs Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Saudi Arabia Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 177. Saudi Arabia Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 178. Saudi Arabia Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 179. Saudi Arabia Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 180. Saudi Arabia Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 181. UAE Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. UAE Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 183. UAE Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 184. UAE Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 185. UAE Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 186. UAE Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 187. South Africa Gastrointestinal Drugs Market, By Value, In USD Billion, 2017-2031F
  • Figure 188. South Africa Gastrointestinal Drugs Market Share (%), By Drug Type, 2017-2031F
  • Figure 189. South Africa Gastrointestinal Drugs Market Share (%), By Drug Class, 2017-2031F
  • Figure 190. South Africa Gastrointestinal Drugs Market Share (%), By Route of Administration, 2017-2031F
  • Figure 191. South Africa Gastrointestinal Drugs Market Share (%), By Application, 2017-2031F
  • Figure 192. South Africa Gastrointestinal Drugs Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 193. By Drug Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 198. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023